Proinflammatory and prothrombotic biomarkers in aPL-positive patients after stopping fluvastatin
| Biomarker (BMR) | # of Patients with increased BMR after stopping fluvastatin (%) | Mean±SD maximum BMR increase after stopping fluvastatin | Mean time (days) to maximum BMR increase after stopping fluvastatin |
|---|---|---|---|
| IL6 (pg/mL) | 9/12 (75%) | 56.7±34.5 | 35±12 |
| IL1β (pg/mL) | 5/6 (83%) | 89.0±23.5* | 43±15 |
| IL8 (pg/mL) | 3/5 (60%) | 45.6±34.1 | 60±10 |
| VEGF (pg/mL) | 5/10 (50%) | 57.8±28.5* | 48±15 |
| TNFα (pg/mL) | 6/9 (67%) | 90.3±4.5* | 58±17 |
| IFNα (pg/mL) | 6/8 (75%) | 56.7±21.0 | 60±20 |
| IP10 (pg/mL) | 8/12 (67%) | 87.5±14.5* | 55±15 |
| sCD40L (pg/mL) | 9/10 (90%) | 90.6±4.3* | 45±15 |
| sTF (pM) | 13/20 (65) | 80.4±10.3* | 50±12 |
| sICAM-1 (ng/mL) | 1/7 (14) | 23.4±12.0 | 60 |
| sVCAM-1 (ng/mL) | 3/4 (75) | 47.6±10.4 | 46±15 |
| sE-sel (ng/mL) | 0/2 (0) | N/A | N/A |
*p<0.05.
IFNα, interferon α; IL, interleukin; IP10, inducible protein 10; N/A, not applicable; sCD40L, soluble CD 40 ligand; sEsel, soluble E-selectin; sICAM-1, soluble intercellular adhesion molecule; sTF, soluble tissue factor; sVCAM-1, soluble vascular cell adhesion molecule 1; TNFα, tumour necrosis factor α; VEGF, vascular endothelial growth factor.